ZaBeCor Moves siRNA-Based Asthma Drug into Phase II

The decision was made after a phase I showed patients experienced no serious adverse effects, while 75 percent of patients reported an “improved ability to breathe freely or reduced use of their rescue inhaler.”

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.